SLC5A2 and metabolic dysfunction-associated steatohepatitis: Our study demonstrated Sglt2 expression in medaka kidney and showed that steatosis and fibrosis were ameliorated, irrespective of the changes in the BW in medaka NASH models treated with Tofo.